Goutham Sunny
@medoncodoc
Asst Prof, Medical Oncology @GCRI_1972 @offcmcvellore alumni #pantumor 🧬🌐, Academic account, #medtwitter. Follow @gsrocks007 for personal account.
Anda mungkin suka
Due to an unexpectedly busy schedule, a few postponed personal commitments and projects, and several fast-approaching deadlines, I’ll be taking a break from posting tweets and updates for the next couple of months. I hope to be back by mid-September. I’ll still be around, reading…
🐘 The elephant in the room: we don’t know how to sequence all these TOPO1 ADCs.
#ESMO25 ADCs in chemo-pretreated HR+/HER2− mBC: Phase 3 studies From Dr. Javier Cortés' great discussion on ADCs👇
Options for HER2-positive breast cancer are increasing🚀🎉 It was announced that maintenance tucatinib combined with HP after THP provides a significant PFS advantage (HER2CLIMB-05) Now we have 3 new options. Minds are confused. Data mining awaits us🤯
INTERLACE or KEYNOTE-A18 for #CervicalCancer ? 🤔 It’s all about patient selection, risk profile, safety and clinical context💡 @OncoAlert
So proud of @jtgeorgy and the whole team at @OffCMCVellore for doing such an impactful and relevant study for India and all LMICs. Truly amazing work 🫡
🚨Out in @SciReports @NaturePortfolio our study from @OffCMCVellore @todrashish Low-dose nivolumab + induction chemo in unresectable/loc advanced HNSCC led to 75 % ORR, 31 % conversion to resectability, ~90 % cost reduction. See below 🧵on our findings👇nature.com/articles/s4159…
Happy to share our experience... What immunotherapy can achieve in advanced non metastatic HNSCC ? hope this will help our patients in india.. 🇮🇳 @ICMRDELHI @csoncol nature.com/articles/s4159…
A quick reckoner on comparison of 1st line TKIs for ALK+ NSCLC. Which one do you use in 1L? Where does brigatinib fit in, with Alectinib being available for lesser cost and Lorlatinib having crazy efficacy? @SuyogCancer @OncBrothers @StephenVLiu @medoncodoc @dr_yakupergun
Bloomberg @business (Global, NY) @RobertLangreth recently featured our work from @OffCMCVellore Medical Oncology & Haematology and @TataMemorial: low-dose immunotherapy and potential for equitable cancer care. What if 1/6th the dose works just as well? bloomberg.com/features/2025-…
I was away from X for ~3 months due to personal work and now have ~2000 publications to catch up on. In oncology, if you don’t stay updated, you risk becoming outdated fast. The pace at which knowledge evolves—and irrelevance sets in—is truly brutal #studentforlife
Nice slide for cross trial comparison Flaura , Flaura 2 amd Marriposa. by Dr Daniel Tan #WCLC2025 . Don't miss the last row .
In our recent post, we provided trial names for AI models to rank as the most anticipated plenary data at WCLC 2025. This time, we asked AI models to independently identify the top 10 most anticipated interventional trials in thoracic oncology expected at @IASLC – WCLC 2025.…
For now… cross trial comparison is all we have! This will come over and over in our clinics for Her2+ non-small cell lung cancer. Sequencing and AE discussions so that our pts can make informed/shared decision (@jillfeldman4 🙏🏽🙏🏽) ! #Zongertinib #TDxD #lcsm #OncTwitter
Zongertinib is now approved for Her2+ NSCLC based off Beamion Lung-1! We had a chance to 🗣️ Her2 testing, trial, findings, AEs and sequencing w/ @JSabari Full 🗣️: ⭐️ Oncbrothers.com/zongertinib-fd… ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm @OncUpdates
Infections in cancer. Addressed 10 key issues. @TataMemorial @ACTREC_TMC @VanitaNoronha @SuyogCancer @Amolpatel_dr @DrNikitaMehra @cspramesh @IJMPOofficial @bagalbp @SirohiBhawna @ajumathew_ ecancer.org/en/journal/art…
Congratulations @jtgeorgy and the whole team involved @OffCMCVellore
📢Our new paper @OffCMCVellore Pathology, MedOnc out in @ecancer doi.org/10.3332/ecance… After Dr. @ullas_batra's report, this is largest Indian series of tepotinib-Rxed METex14 mNSCLC. Led by @todrashish, Dr. Rekha Pai @ajoel_84, Dr. Rohini @ajoyojohn Dr. Deepa Susan #LCSM
Hepatic metastases management: A comparative review of surgical resection, thermal ablation, and stereotactic body radiation therapy Eur J Cancer doi.org/10.1016/j.ejca… 🔎narrative review 👉multiple complementary options 👉Surgery most effective, but RFA & SBRT valid…
🚨 Potential Practice Changer in #BladderCancer 🚨 KEYNOTE-905 (EV-303) – cisplatin-ineligible MIBC Peri-op pembrolizumab + enfortumab vedotin vs surgery alone: ✅ ↑ Event-Free Survival ✅ ↑ Overall Survival ✅ ↑ Pathologic CR rates 📌 First Phase 3 to show survival benefit…
VIKTORIA-1 trial: Gedatolisib (dual PI3K/mTOR inhibitor) + fulvestrant ± palbo in HR+/HER2–, PIK3CA WT ABC, post-CDK4/6i. Prees relase . 📊 Triplet mPFS: 9.3 mo ⚪ Fulvestrant: 2.0 mo 🟢 Delta: +7.3 mo | HR: 0.24 But is that delta real? 🤔 📉 Fulvestrant-only arms in other…
Even though I've used SG only once and I've never used DatoDxD - as an academic exercise I wanted to review the ADR profile of both ADCs. Made a small infographic card for the same. Hope it is useful for ppl who need it. @OncBrothers @SuyogCancer @PTarantinoMD @dr_yakupergun
United States Tren
- 1. Justin Fields 9,397 posts
- 2. #FinallyOverIt 1,563 posts
- 3. Jets 67.2K posts
- 4. Patriots 144K posts
- 5. Drake Maye 19.3K posts
- 6. Jalen Johnson 5,935 posts
- 7. Henderson 21.4K posts
- 8. AD Mitchell 2,303 posts
- 9. Judge 186K posts
- 10. Summer Walker 10.2K posts
- 11. Pats 14.2K posts
- 12. 5sos 17.3K posts
- 13. #criticalrolespoilers 2,455 posts
- 14. Diggs 10.4K posts
- 15. Cal Raleigh 7,534 posts
- 16. Santana 13.7K posts
- 17. 1-800 Heartbreak N/A
- 18. #GreysAnatomy 2,090 posts
- 19. #zzzSpecialProgram N/A
- 20. #TNFonPrime 3,394 posts
Anda mungkin suka
-
Ashish Singh
@todrashish -
Kevin John John, MD MRCP
@drkevinjj -
Prof. (Dr.) Uma Kumar
@_Rheuma -
Vijay Alexander
@VijayAlexander9 -
Dr Deepak Krishnamurthy
@DrDeepakKrishn1 -
Dr P Kamath
@cardio73 -
Mithun Abraham Prakash
@mithunap11 -
Josh Thomas Georgy
@jtgeorgy -
Arun George
@arun09cmc -
Dr. Rahul Baxi
@baxirahul -
Yu Yang Soon
@yysoon01 -
Dr Ambrish Mithal
@DrAmbrishMithal -
TheSpeakingScalpel
@DrSaurav5 -
Malathy Iyer
@MalathyIyerTOI -
Pramesh CS
@cspramesh
Something went wrong.
Something went wrong.